Reporting of health-related quality of life endpoints in National Cancer Institute-supported cancer treatment trials.
National Cancer Institute
clinical trials
health-related quality of life (HRQOL)
patient-reported outcome
publications
Journal
Cancer
ISSN: 1097-0142
Titre abrégé: Cancer
Pays: United States
ID NLM: 0374236
Informations de publication
Date de publication:
01 06 2020
01 06 2020
Historique:
received:
04
06
2019
revised:
10
07
2019
accepted:
17
09
2019
pubmed:
3
4
2020
medline:
23
1
2021
entrez:
3
4
2020
Statut:
ppublish
Résumé
The importance of capturing and reporting health-related quality of life (HRQOL) in clinical trials has been increasingly recognized in the oncology field. As a result, the National Cancer Institute (NCI) began to provide support for correlative HRQOL studies in cancer treatment trials. The current study was conducted to assess the publication rate of HRQOL correlative studies in NCI-supported treatment trials and to identify potential factors positively or negatively associated with publication rates. The NCI conducted a retrospective review of existing NCI databases to identify cancer treatment trials that had obtained additional NCI funding for the assessment of HRQOL and to determine the extent to which funded HRQOL studies have been completed and published in a peer-reviewed journal. Of the 108 included trials, 58 (54%) had a parent trial (PT) publication; of these, 36 trials (62%) had a published HRQOL result: 20 as an independent publication and 16 that were included and/or reported in the PT publication. The length of time between trial activation and closure, as well as the specific cancer, appeared to be associated with the publication rates. The results of the current study demonstrated that approximately 45% of the PT publications were followed by a HRQOL publication within 1 year, to allow the knowledge to be used in patient treatment decision making. The authors believe the current analysis is an important first step toward a better understand of the challenges that researchers face when reporting HRQOL endpoints.
Sections du résumé
BACKGROUND
The importance of capturing and reporting health-related quality of life (HRQOL) in clinical trials has been increasingly recognized in the oncology field. As a result, the National Cancer Institute (NCI) began to provide support for correlative HRQOL studies in cancer treatment trials. The current study was conducted to assess the publication rate of HRQOL correlative studies in NCI-supported treatment trials and to identify potential factors positively or negatively associated with publication rates.
METHODS
The NCI conducted a retrospective review of existing NCI databases to identify cancer treatment trials that had obtained additional NCI funding for the assessment of HRQOL and to determine the extent to which funded HRQOL studies have been completed and published in a peer-reviewed journal.
RESULTS
Of the 108 included trials, 58 (54%) had a parent trial (PT) publication; of these, 36 trials (62%) had a published HRQOL result: 20 as an independent publication and 16 that were included and/or reported in the PT publication. The length of time between trial activation and closure, as well as the specific cancer, appeared to be associated with the publication rates.
CONCLUSIONS
The results of the current study demonstrated that approximately 45% of the PT publications were followed by a HRQOL publication within 1 year, to allow the knowledge to be used in patient treatment decision making. The authors believe the current analysis is an important first step toward a better understand of the challenges that researchers face when reporting HRQOL endpoints.
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
2687-2693Commentaires et corrections
Type : CommentIn
Informations de copyright
© 2020 American Cancer Society.
Références
National Cancer Institute. What are clinical trials? Updated June 2016. Accessed November 5, 2018. https://www.cancer.gov/about-cancer/treatment/clinical-trials/what-are-trials
Nayfield SG, Ganz PA, Moinpour CM, Cella DF, Hailey BJ. Report from a National Cancer Institute (USA) workshop on quality of life assessment in cancer clinical trials. Qual Life Res. 1992;1:203-210.
Ganz PA. Long-range effect of clinical trial interventions on quality of life. Cancer. 1994;74(suppl 9):2620-2624.
Buchanan DR, O’Mara AM, Kelaghan JW, Minasian LM. Quality-of-life assessment in the symptom management trials of the National Cancer Institute-supported Community Clinical Oncology Program. J Clin Oncol. 2005;23:591-598.
Brundage M, Osoba D, Bezjak A, Tu D, Palmer M, Pater J; National Cancer Institute of Canada Clinical Trials Group. Lessons learned in the assessment of health-related quality of life: selected examples from the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol. 2007;25:5078-5081.
Au HJ, Ringash J, Brundage M, Palmer M, Richardson H, Meyer RM; NCIC CTG Quality of Life Committee. Added value of health-related quality of life measurement in cancer clinical trials: the experience of the NCIC CTG. Expert Rev Pharmacoecon Outcomes Res. 2010;10:119-128. doi:10.1586/erp.10.15
Ter Veer E, van Kleef JJ, Sprangers MAG, Haj Mohammad N, van Oijen MGH, van Laarhoven HWM. Reporting of health-related quality of life in randomized controlled trials involving palliative systemic therapy for esophagogastric cancer: a systematic review. Gastric Cancer. 2018;21:183-195. doi:10.1007/s10120-018-0792-3
Secord AA, Coleman RL, Havrilesky LJ, Abernethy AP, Samsa GP, Cella D. Patient-reported outcomes as end points and outcome indicators in solid tumors. Nat Rev Clin Oncol. 2015;12:358-370. doi:10.1038/nrclinonc.2015.29
Ediebah DE, Quinten C, Coens C, et al; Canadian Cancer Trials Group and the European Organization for Research and Treatment of Cancer. Quality of life as a prognostic indicator of survival: a pooled analysis of individual patient data from Canadian Cancer Trials Group clinical trials. Cancer. 2018;124:3409-3416. doi:10.1002/cncr.31556
Ganz PA, Cecchini RS, Julian TB, et al. Patient-reported outcomes with anastrozole versus tamoxifen for postmenopausal patients with ductal carcinoma in situ treated with lumpectomy plus radiotherapy (NSABP B-35): a randomised, double-blind, phase 3 clinical trial. Lancet. 2015;387:857-865.
Wagner LI, Zhao F, Goss PE, et al. Patient-reported predictors of early treatment discontinuation: treatment-related symptoms and health-related quality of life among postmenopausal women with primary breast cancer randomized to anastrozole or exemestane on NCIC Clinical Trials Group (CCTG) MA.27 (E1Z03). Breast Cancer Res Treat. 2018;169:537-548. doi:10.1007/s10549-018-4713-2
Schandelmaier S, Conen K, von Elm E, et al; DISCO study group. Planning and reporting of quality-of-life outcomes in cancer trials. Ann Oncol. 2015;26:1966-1973. doi:10.1093/annonc/mdv283
Klein J, Livergant J, Ringash J. Health related quality of life in head and neck cancer treated with radiation therapy with or without chemotherapy: a systematic review. Oral Oncol. 2014;50:254-262. doi:10.1016/j.oraloncology.2014.01.015
Smith AB, Cocks K, Parry D, Taylor M. Reporting of health-related quality of life (HRQOL) data in oncology trials: a comparison of the European Organization for Research and Treatment of Cancer Quality of Life (EORTC QLQ-C30) and the Functional Assessment of Cancer Therapy-General (FACT-G). Qual Life Res. 2014;23:971-976. doi:10.1007/s11136-013-0534-2
National Cancer Institute. NCTN: NCI's National Clinical Trials Network. Updated October 2018. Accessed November 19, 2018. https://www.cancer.gov/research/areas/clinical-trials/nctn
O’Mara AM, Denicoff AM. Health related quality of life in NCI-sponsored cancer treatment trials. Semin Oncol Nurs. 2010;26:68-78. doi:10.1016/j.soncn.2009.11.009
National Cancer Institute. Community Oncology Research Program (NCORP). Updated November 2018. Accessed December 18, 2018. https://ncorp.cancer.gov/
Adamowicz K, Saad ED, Jassem J. Health-related quality of life assessment in contemporary phase III trials in advanced colorectal cancer. Cancer Treat Rev. 2016;50:194-199. doi:10.1016/j.ctrv.2016.09.015
Bottomley A, Pe M, Sloan J, et al. Moving forward toward standardizing analysis of quality of life data in randomized cancer clinical trials. Clin Trials. 2018;15:624-630. doi:10.1177/1740774518795637
Dwan K, Gamble C, Williamson PR, Kirkham JJ; Reporting Bias Group. Systematic review of the empirical evidence of study publication bias and outcome reporting bias-an updated review. PLoS One. 2013;8:e66844.
Smyth RM, Kirkham JJ, Jacoby A, Altman DG, Gamble C, Williamson PR. Frequency and reasons for outcome reporting bias in clinical trials: interviews with trialists. BMJ. 2011;342:c7153.
Marandino L, La Salvia A, Sonetto C. Deficiencies in health-related quality of life assessment and reporting: a systematic review of oncology randomized phase III trials published between 2012 and 2016. Ann Oncol. 2018;29:2288-2295. doi:10.1093/annonc/mdy449
Bylicki O, Gan HK, Joly F, Maillet D, You B, Peron J. Poor patient-reported outcomes reporting according to CONSORT guidelines in randomized clinical trials evaluating systemic cancer therapy. Ann Oncol. 2015;26:231-237. doi:10.1093/annonc/mdu489
Calvert M, Kyte D, Mercieca-Bebber R, et al. Guidelines for inclusion of patient-reported outcomes in clinical trial protocols: the SPIRIT-PRO Extension. JAMA. 2018;319:483-494. doi:10.1001/jama.2017.21903
Bottomley A, Pe M, Sloan J, et al; Setting International Standards in Analyzing Patient-Reported Outcomes and Quality of Life Endpoints Data (SISAQOL) consortium. Analysing data from patient-reported outcome and quality of life endpoints for cancer clinical trials: a start in setting international standards. Lancet Oncol. 2016;17:e510-e514. doi:10.1016/S1470-2045(16)30510-1